PLEDGE AND SECURITY AGREEMENT MADE BY THERAVANCE BIOPHARMA R&D, INC., AS EQUITYHOLDER, IN FAVOR OF U.S. BANK NATIONAL ASSOCIATION, A NATIONAL BANKING ASSOCIATION, AS TRUSTEE Dated as of February 28, 2020Pledge and Security Agreement • March 4th, 2020 • Theravance Biopharma, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMarch 4th, 2020 Company Industry JurisdictionThis PLEDGE AND SECURITY AGREEMENT, dated as of February 28, 2020 (this “Pledge and Security Agreement”), is made by Theravance Biopharma R&D, Inc., a Cayman Islands exempted company (“Theravance Biopharma R&D”), as the equityholder (in such capacity, the “Equityholder”) of Triple Royalty Sub II LLC, a Delaware limited liability company, as the issuer (the “Issuer”), in favor of U.S. Bank National Association, a national banking association, not in its individual capacity but solely as the trustee (the “Trustee”) under the Indenture, dated as of the date hereof, by and between the Issuer, the Trustee, and solely with respect to Sections 2.11(o) and 2.11(p) thereof, Theravance Biopharma, Inc., a Cayman Islands exempted company.
PLEDGE AND SECURITY AGREEMENT MADE BY THERAVANCE BIOPHARMA R&D, INC., AS EQUITYHOLDER, IN FAVOR OF U.S. BANK NATIONAL ASSOCIATION, A NATIONAL BANKING ASSOCIATION, AS TRUSTEE Dated as of November 30, 2018Pledge and Security Agreement • December 3rd, 2018 • Theravance Biopharma, Inc. • Pharmaceutical preparations • New York
Contract Type FiledDecember 3rd, 2018 Company Industry JurisdictionThis PLEDGE AND SECURITY AGREEMENT, dated as of November 30, 2018 (this “Pledge and Security Agreement”), is made by Theravance Biopharma R&D, Inc., a Cayman Islands exempted company (“Theravance Biopharma R&D”), as the equityholder (in such capacity, the “Equityholder”) of Triple Royalty Sub LLC, a Delaware limited liability company, as the issuer (the “Issuer”), in favor of U.S. Bank National Association, a national banking association, not in its individual capacity but solely as the trustee (the “Trustee”) under the Indenture, dated as of the date hereof, by and between the Issuer and the Trustee.